Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.52 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319946 | 0.83 | CYP26A1 (0.45) | GABBR2GABBR1FFAR1 | |
| SCHEMBL5320805 | 0.82 | UGT2B7 (0.49) | ADRA2AADRA2CHIF1A | |
| SCHEMBL5144343 | 0.81 | GABBR2 (0.52) | GABBR2GABBR1CYP2C19FFAR1ADRA2A | |
| SCHEMBL7320534 | 0.80 | GABBR2 (0.47) | GABBR2GABBR1CYP2C19FFAR1HTT | |
| SCHEMBL10022854 | 0.80 | GABBR2 (0.55) | GABBR2GABBR1CYP2C19MAPT | |
| SCHEMBL618203 | 0.80 | GABBR2 (0.55) | GABBR2GABBR1CYP2C19MAPT | |
| SCHEMBL618204 | 0.80 | GABBR2 (0.55) | GABBR2GABBR1CYP2C19MAPT | |
| 3,3-Diphenylpropanoic Acid SCHEMBL20981393 | 0.80 | FFAR1 (0.59) | GABBR2GABBR1CYP2C19FFAR1ADRA2A | |
| SCHEMBL5327684 | 0.79 | CTSA (0.43) | — | |
| SCHEMBL7876564 | 0.78 | GABBR2 (0.53) | GABBR2GABBR1CYP2C19ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | claimed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | claimed |
| CN-1300213-A | Solid composition containing gamma-aminobutyric acid derivative and preparation method thereof | WARNER LAMBERT CO (US) | 2001-06-20 | — | — | CN | claimed |
| WO-2011038469-A1 | SUPPRESSIVE AGENTS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010088729-A1 | COMPOSITIONS AND USES THEREFOR | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010022444-A1 | METHODS AND AGENTS FOR MODULATING KINASE SIGNALLING PATHWAYS THROUGH MODULATION OF MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN (MLKL) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090215669-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2009-08-27 | — | — | US | disclosed |
| WO-2009021289-A1 | POTASSIUM CHANNEL INHIBITORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | WO | disclosed |
| EP-1962882-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | Dia-B Tech Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008025069-A1 | METHODS OF MODULATING CELLULAR ACTIVITY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | WO | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007025332-A1 | A PEPTIDE AND ZINC ION COMPOSITION FOR TREATING DIABETES AND ENHANCING IMMUNE FUNCTION | DIA-B TECH LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032417-A1 | Peptides and therapeutic uses thereof | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-02-08 | — | — | US | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| CN-1575817-A | Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same | WARNER LAMBERT CO (US) | 2005-02-09 | — | — | CN | disclosed |
| WO-2004089362-A1 | 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| CN-1171587-C | Solid composition containing gamma-aminobutyric acid derivative and preparation method thereof | ��ʲ | 2004-10-20 | — | — | CN | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | disclosed |
| CN-1300213-A | Solid composition containing gamma-aminobutyric acid derivative and preparation method thereof | WARNER LAMBERT CO (US) | 2001-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032417-A1 | Peptides and therapeutic uses thereof | BCL2, BAX, BCL2L13 | GABBR2 3067/4885GABBR1 3885/4885CYP2C19 4825/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | GABBR2 4665/4885GABBR1 4808/4885CYP2C19 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.